On Tuesday, Gilead Sciences, Inc. (GILD) stock saw a modest uptick, ending the day at $90.22 which represents a slight increase of $0.38 or 0.42% from the prior close of $89.84. The stock opened at ...

Gilead stock surges after Q3 earnings beat estimates and raised FY 2024 guidance, with strong HIV drug sales and analyst ...

Fintel reports that on November 8, 2024, Maxim Group downgraded their outlook for Gilead Sciences (NasdaqGS:GILD) from Buy to ...

GILD) shares, increasing the price target to $105 from $95, while reiterating an Overweight rating on the stock. The revision followed Gilead's third-quarter earnings that surpassed expectations ...

Maxim downgraded Gilead (GILD) to Hold from Buy. The stock has appreciated significantly following a pullback in the first half of the year, ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Leerink Partners analyst Daina Graybosch has maintained their bullish stance on GILD stock, giving a Buy rating yesterday. Daina ...

Headquartered in Foster City, California, Gilead Sciences, Inc. (GILD) is a prominent biopharmaceutical company with a market ...

Gilead Sciences (NASDAQ ... that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast). Past Earnings Performance During the last ...